Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults who are 21 to 64 years of age (inclusive) at the time of first study vaccination.~* Written informed consent obtained from the subject.~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* Healthy subjects as established by medical history and physical examination.~* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.~* For subjects who undergo a screening visit, results of all safety laboratory tests obtained at the screening visit must be within reference ranges. Results of any repeat testing cannot be used to qualify a subject for enrollment.~* Female subjects of non-childbearing potential may be enrolled in the study. Non-childbearing potential is defined as current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if they~  * have practiced adequate contraception for 30 days prior to vaccination, and~ * have a negative pregnancy test on the day of vaccination, and~ * agree to continue to practice adequate contraception until 2 months after the last dose administered.~Exclusion Criteria:~* Presence or evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.~* Presence or evidence of substance abuse.~* Diagnosed with cancer, or treatment for cancer within three years.~  1. Persons with a history of cancer who are disease-free without treatment for three years or more are eligible.~ 2. Persons with a history of histologically-confirmed basal cell carcinoma of the skin successfully treated with local excision only are excepted and are eligible, but other histologic types of skin cancer are exclusionary.~ 3. Women who are disease-free three years or more after treatment for breast cancer and receiving long-term prophylaxis are eligible.~* Diagnosed with excessive daytime sleepiness (unintended sleep episodes during the day present almost daily for at least one month), or narcolepsy.~* History of narcolepsy in subject's parent, sibling or child~* Presence of a temperature ≥ 38.0ºC (≥100.4ºF), or acute symptoms greater than mild severity on the scheduled date of first vaccination.~NOTE: The subject may be vaccinated at a later date, provided symptoms have resolved, and all other eligibility criteria continue to be satisfied.~* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.~* Receipt of systemic glucocorticoids within 30 days prior to the first dose of study vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs within 6 months of first study vaccine/ placebo dose. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed.~* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.~* An acute evolving neurological disorder or Guillain Barré Syndrome within 42 days of receipt of prior seasonal or pandemic influenza vaccine.~* Administration of an inactive vaccine within 14 days or of a live attenuated vaccine within 30 days before the first dose of study vaccine/placebo.~* Planned administration of any vaccine other than the study vaccine/placebo before blood sampling at the Day 42 visit.~* Previous administration of any H7 vaccine or physician-confirmed H7 disease.~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.~* Receipt of any immunoglobulins and/or any blood products within 90 days before the first dose of study vaccine/placebo, or planned administration of any of these products during the study period.~* Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine including a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.~* Known pregnancy or a positive urine beta-human chorionic gonadotropin (β-hCG) test result before the first dose of study vaccine/placebo.~* Lactating or nursing women.~* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Formulation 1 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 1 at a 21 day interval
- Formulation 2 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 2 at a 21 day interval
- Formulation 3 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 3 at a 21 day interval
- Formulation 4 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK2789869A H7N1 vaccine formulation 4 at a 21 day interval
- Formulation 5 Group (Type: EXPERIMENTAL): Subjects in this group will receive two doses of GSK2789868A H7N1 vaccine formulation 5 at a 21 day interval
- Placebo Group (Type: PLACEBO_COMPARATOR): Subjects in this group will receive two doses of placebo at a 21 day interval

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete